Corient Private Wealth LLC Has $9.33 Million Stake in Cencora, Inc. (NYSE:COR)

Corient Private Wealth LLC increased its stake in Cencora, Inc. (NYSE:COR - Free Report) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 41,517 shares of the company's stock after buying an additional 1,378 shares during the period. Corient Private Wealth LLC's holdings in Cencora were worth $9,328,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Envestnet Portfolio Solutions Inc. increased its stake in shares of Cencora by 5.9% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 18,245 shares of the company's stock worth $4,099,000 after buying an additional 1,021 shares during the last quarter. Natixis Advisors LLC grew its position in shares of Cencora by 2.7% during the fourth quarter. Natixis Advisors LLC now owns 142,828 shares of the company's stock worth $32,091,000 after acquiring an additional 3,800 shares during the last quarter. Hills Bank & Trust Co grew its position in shares of Cencora by 3.7% during the fourth quarter. Hills Bank & Trust Co now owns 7,216 shares of the company's stock worth $1,621,000 after acquiring an additional 260 shares during the last quarter. Aviso Financial Inc. grew its position in shares of Cencora by 21.2% during the fourth quarter. Aviso Financial Inc. now owns 7,464 shares of the company's stock worth $1,677,000 after acquiring an additional 1,305 shares during the last quarter. Finally, CFO4Life Group LLC grew its position in shares of Cencora by 7.2% during the fourth quarter. CFO4Life Group LLC now owns 1,293 shares of the company's stock worth $291,000 after acquiring an additional 87 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on COR shares. Mizuho started coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target for the company. Wells Fargo & Company upped their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Finally, StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and an average target price of $280.20.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares in the company, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 11,970 shares of company stock valued at $2,998,670. 10.80% of the stock is owned by insiders.

Cencora Price Performance

NYSE COR traded down $0.93 on Friday, reaching $266.91. The company's stock had a trading volume of 6,526,576 shares, compared to its average volume of 1,379,194. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $271.08. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market cap of $51.76 billion, a PE ratio of 37.97, a PEG ratio of 1.31 and a beta of 0.51. The firm's 50 day moving average is $250.62 and its two-hundred day moving average is $240.03.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.